Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status

PD-L1 expression in nonclear-cell renal cell carcinoma

(2014) T. K. Choueiri et al.   ANNALS OF ONCOLOGY

Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation

(2014) Miguel F. Sanmamed et al.   CANCER JOURNAL

Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial

(2014) T. K. Choueiri et al.   CLINICAL CANCER RESEARCH

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

(2014) Muhammad Zaeem Noman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence

(2014) Scott Tykodi   OncoTargets and Therapy

A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells

(2013) I. B. Barsoum et al.   CANCER RESEARCH

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Programmed Death Ligand 2 in Cancer-Induced Immune Suppression

(2012) Esdy N. Rozali et al.   Clinical & Developmental Immunology

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

(2012) X. Jiang et al.   CLINICAL CANCER RESEARCH

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells

(2010) W. Hobo et al.   BLOOD

PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1

(2010) M. Ghiotto et al.   INTERNATIONAL IMMUNOLOGY

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Renal cell carcinoma

(2009) Brian I Rini et al.   LANCET

Advances and controversies in grading and staging of renal cell carcinoma

(2009) Brett Delahunt   MODERN PATHOLOGY

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA